Seattle Genetics (SGEN) Earning Somewhat Positive Media Coverage, Study Shows

News headlines about Seattle Genetics (NASDAQ:SGEN) have trended somewhat positive on Friday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Seattle Genetics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.0628134111458 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news headlines that may have impacted Accern’s scoring:

Several equities analysts have recently issued reports on SGEN shares. Cann started coverage on Seattle Genetics in a research note on Wednesday, November 8th. They set a “hold” rating on the stock. Oppenheimer reissued a “hold” rating on shares of Seattle Genetics in a research note on Thursday, December 7th. Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Seattle Genetics in a research note on Monday, October 23rd. BidaskClub raised Seattle Genetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 9th. Finally, TheStreet raised Seattle Genetics from a “d” rating to a “c” rating in a research note on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $63.76.

Shares of Seattle Genetics (NASDAQ:SGEN) opened at $53.45 on Friday. The firm has a market capitalization of $7,690.00, a price-to-earnings ratio of -61.44 and a beta of 2.37. Seattle Genetics has a 12 month low of $45.31 and a 12 month high of $71.32.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.23. The company had revenue of $135.29 million for the quarter, compared to analysts’ expectations of $112.76 million. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. The firm’s revenue for the quarter was up 27.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.23) earnings per share. analysts predict that Seattle Genetics will post -0.93 EPS for the current fiscal year.

In other Seattle Genetics news, insider Clay B. Siegall sold 18,832 shares of the business’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $58.00, for a total value of $1,092,256.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Todd E. Simpson sold 39,385 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $60.91, for a total value of $2,398,940.35. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 157,210 shares of company stock worth $9,094,911. 34.70% of the stock is owned by insiders.

WARNING: This story was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit